NPK International lowered its full-year 2026 Adjusted EBITDA guidance from $97-$103 million to $90-$93 million, reducing the high end by $10 million. This revision caused the company's shares to fall about 21.9% in after-hours trading. The company also reduced its revenue forecast for 2026 from $313-$323 million to $300-$305 million. An investigation by Levi & Korsinsky, LLP is ongoing to determine if NPKI made misleading statements affecting investors, who may be eligible to seek recovery for losses whether they sold shares or still hold them.
NPK International's recent securities investigation notice provides context for readers. For those following the Industrials sector, 79 of 135 US stocks traded on Pluang rose while 56 fell as of Nov 06, 2026 21:51 WIB. Notable gainers include FCEL at USD 9.84 with a 10.19% increase and 68% buy order activity, LUNR at USD 9.46 up 9.74% with 100% buy orders, and FIX at USD 1,055.06 rising 9.34% with 98% buy orders.
Kendal Nutricare Limited will be referred to government and state agencies after refusing to participate in a compliance inquiry by the BBB National Programs’ National Advertising Division. The inquiry followed a challenge by Abbott Laboratories rega...
The Mexico animal healthcare market is projected to grow from $2.13 billion in 2025 to $3.34 billion by 2031, at a CAGR of 7.84%. Growth is fueled by rising spending on companion animals, expanding livestock production, and innovations in veterinary ...
Rainforest Distribution Corp. has implemented Samsara Route Planning and Commercial Navigation across its direct-store-delivery fleet, unifying routing, navigation, telematics, and compliance on one platform integrated with its SAP system. This upgra...
BriaCell Therapeutics and its subsidiary BriaPro presented positive preclinical data at the SITC 2026 Annual Meeting, highlighting their immunotherapy platforms Bria-OTS+ and BP-80. Bria-OTS+ showed broad immune activation and sustained cancer cell k...
Canary Capital has launched the Canary Staked INJ ETF (INJC) on Nasdaq, providing investors exposure to INJ, the native token of the Injective blockchain. The ETF not only tracks INJ's price but also earns staking rewards from the network's proof-of-...
